Over a Baltimore Crab Cake Platter, Our Tech Guru Told Me About This Surging Biotech

Today marks exactly two months since we recommended Emergent BioSolutions Inc. (NYSE: EBS) - which we pitched as an "immunotherapy stock with a twist."

In that short stretch, Emergent is up 25.5%. That's an annualized return of 153%.

And there's more to come...

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK